FSN secures majority stake in Adragos Pharma

  • by


FSN Capital has acquired a majority stake in Adragos Pharma, a Germany-based B2B contract developer and manufacturer (CDMO) for pharmaceuticals.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *